teaser produits: TG4070TG4070 is the second Individualized Neoantigen Therapeutic Vaccine from our proprietary myvac® discovery platform.The randomized Phase 1 will evaluate TG4070 in combination with nivolumab in resected non-small cell lung cancer (NSCLC) patients.More information on the Clinical Trial in the European Union – EMA EUCT2025-520946-31-00Read more about TG4070Discover TG4070